BACKGROUND: @entity980 ( @entity980 ) of the parotid region is rare and to the authors' knowledge little information is available regarding the site of @entity5 origin, clinical presentation, and outcome in these @entity1 . Therefore, the authors reviewed the files of all @entity1 with @entity980 of the parotid region who were registered on the Intergroup @entity980 Studies (IRS) I-IV. METHODS: @entity1 charts and the Intergroup @entity980 Study Group (IRSG) database were reviewed. RESULTS: Sixty-two @entity1 presenting with a mass in the parotid region were identified. None of the @entity5 was localized exclusively to the parotid gland, so the primary site was referred to as the "parotid region." The @entity5 invaded a parameningeal site in 30 @entity1 . These cases have been designated as @entity5 to distinguish them from 32 cases that did not invade a parameningeal site and were designated as @entity5 . The majority of @entity1 had @entity5 in both the nonparameningeal-parotid and @entity27689 subgroups. However, although there were 16 @entity1 with Group I or II @entity5 in the nonparameningeal-parotid subgroup, no @entity1 with Group I or II @entity5 were found in the @entity27689 subgroup (P = 0.001). Fifty-six of 62 @entity1 (90%) received radiotherapy. The parameningeal primary site designation resulted in intensification of both chemotherapy and radiotherapy for @entity1 with @entity980 . The 5-year failure-free survival rate was 81% and the 5-year survival rate was 84%. There were no deaths reported among @entity1 with Group I or II @entity5 . The 5-year failure-free survival did not appear to differ when comparing @entity1 with @entity5 with @entity1 with @entity5 (P = 0.21). CONCLUSIONS: Treatment as defined by the IRS protocols has been reported to be highly effective for @entity1 with @entity980 of the parotid region. Outcome for the more aggressively treated @entity1 with @entity980 appears similar to that for @entity1 with nonparameningeal-parotid @entity980 .

XXXX of the parotid region occurring in childhood and adolescence. A report from the Intergroup @entity980 Study Group.

@entity980 :: ('MESH:D012208', 'Disease') :: ['RMS', 'Rhabdomyosarcoma', 'parameningeal-parotid RMS'] @entity1 :: ('9606', 'Species') :: ['patients', 'Patient'] @entity27689 :: ('MESH:D020819', 'Disease') :: ['parameningeal-parotid'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'nonparameningeal-parotid tumors', 'Group III tumors', 'parameningeal-parotid tumors', 'tumors']
@entity980 :: (MESH:D012208,Disease) :: ['Rhabdomyosarcoma']
